2-Methyl-3-butenyl-1-pyrophosphoric acid salt and agent for treating lymphocytes
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsYoshimasa Tanaka, Takehiko Uchiyama
Life of this patent
Estimating the term…
Abstract
A pharmaceutically acceptable salt of 2-methyl-3-butenyl-l-pyrophosphoric acid; an agent for treating lymphocytes which comprises at least one of 2-methyl-3-butenyl-l-pyrophosphoric acid, a pharmaceutically acceptable salt thereof, and a hydrate thereof; Vγ2Vδ2 type T cells treated by the same; and a medicine containing the same specifically stimulate and proliferate the human Vγ2Vδ2 type T cells, and also induce and enhance an antitumor activity thereof.
Claims9
Vγ2Vδ2 type T cells treated by an agent for treating lymphocytes comprising an agent for treating lymphocytes containing at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof or a hydrate thereof.
A pharmaceutical composition comprising Vγ2Vδ2 type T cells treated with an agent for treating lymphocytes containing at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof or a hydrate thereof and a pharmaceutically acceptable carrier.
A method of treating a patient in need thereof comprising administering an effective amount of a pharmaceutical composition comprising Vγ2Vδ2 type T cells treated with an agent for treating lymphocytes containing at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof or a hydrate thereof and a pharmaceutically acceptable carrier.
A method of treating human lymphocytes, comprising:
- treating peripheral blood from a human with an agent which comprises at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof and a hydrate thereof, thereby stimulating Vγ2Vδ2 type T cells present in said perpheral blood.
Dependencies are inferred from the claim text.